Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22288174 | 0.96 | L3MBTL1 (0.56) | L3MBTL1ABL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL20623030 | 0.94 | L3MBTL1 (0.58) | L3MBTL1ABL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL22288137 | 0.94 | L3MBTL1 (0.58) | L3MBTL1ABL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL30452394 | 0.94 | L3MBTL1 (0.58) | L3MBTL1ABL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL1536419 | 0.92 | CYP1A2 (0.47) | L3MBTL1ABL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL10834084 | 0.85 | HRH4 (0.46) | L3MBTL1ABL1CYP1A2KDM4EHTR3A | |
| SCHEMBL12533934 | 0.84 | CYP1A2 (0.47) | L3MBTL1CYP1A2CYP2A6PDPK1TDP1 | |
| SCHEMBL12533933 | 0.84 | CYP1A2 (0.47) | L3MBTL1CYP1A2CYP2A6PDPK1TDP1 | |
| SCHEMBL12533940 | 0.84 | CYP1A2 (0.47) | L3MBTL1CYP1A2CYP2A6PDPK1TDP1 | |
| SCHEMBL12533935 | 0.84 | CYP1A2 (0.47) | L3MBTL1CYP1A2CYP2A6PDPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7704994-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-7696193-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | disclosed |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK J | 2007-12-27 | — | — | US | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | L3MBTL1 2914/4885ABL1 1718/4885CYP1A2 79/4885 |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | L3MBTL1 2345/4885ABL1 2018/4885CYP1A2 429/4885 |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | L3MBTL1 2345/4885ABL1 2018/4885CYP1A2 429/4885 |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, TPH1, GRIN2B | L3MBTL1 1495/4885ABL1 1466/4885CYP1A2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.